ERBB2 and breast carcinoma: DESTINY-Breast06 directly compares standard-of-care chemotherapy to T-DXd for HR+/HER2-low or HR+/HER2-ultralow (defined as IHC 0 with minimal (<1+) membrane staining) advanced breast cancers after one or more lines of endocrine therapy.